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In situ PCR and in situ reverse transcription PCR (RT-PCR) were applied to discriminate be-
tween latent and productive infection of human cytomegalovirus (HCMV) in leukocytes. We in-
vestigated 28 samples, in which viral pp65 antigen was detected only in the cytoplasm of leuko-
cytes. Additionally we assayed 12 specimens lacking pp65 antigen. Using nested PCR (nPCR), vi-
ral DNA was detected in 27 samples. In six samples the results of nPCR were unreadable due to 
the presence of polymerase inhibitors. By application of in situ PCR, we were able to confirm the 
presence of viral DNA in the nucleus and/or cytoplasm. Productive infection was recognized in 
20 samples in which transcripts for late viral genes were detected. Among the 20 samples nega-
tive by in situ RT-PCR, we recognized phagocytosis of viral particles in eight and the latent form 
of HCMV infection in five.
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INTRODUCTION
Human cytomegalovirus (HCMV) infection 
remains a major problem in immuno-compromised 
patients, such as bone marrow or solid organ recipi-
ents and those suffering from AIDS (Alford & Britt, 
1996). Following primary infection, HCMV estab-
lishes lifelong latency, which is controlled by a func-
tioning immune system. Immunodeficiency leads to 
increased levels of HCMV replication and can cause 
severe, life-threatening diseases (Hengel et al., 1998; 
Streblow & Nelson, 2003).
Development of a diagnostic test that cor-
rectly indicates the risk of HCMV disease is very 
important in the success of preemptive or prophy-
lactic therapy. Rapid, sensitive, specific and reliable 
diagnostic assays for HCMV detection are essential 
for achieving these goals (Boeckh & Boivin, 1998). 
Quantitative methods that assess viremia, including 
antigenemia assay and PCR techniques (DNAemia), 
are recommended in patients at risk for HCMV dis-
ease for early diagnosis and monitoring of antiviral 
treatment (Schafer et al., 1997; Preiser et al., 2001; Ra-
zonable et al., 2002).
The antigenemia assay is based on direct de-
tection of HCMV phosphoprotein 65 (pp65 antigen), 
which is found in the nucleus of leukocytes during 
active infection (Gerna et al., 1992; Perez et al., 1994). 
Our own and those of others observations reveal 
that pp65 antigen is also found in the cytoplasm 
quite frequently, which may be a result of phago-
cytosis or accumulation of virions in the replicative 
cycle (Kas-Deelen et al., 2001). 
To explain this phenomenon we used addi-
tional methods such as nested PCR (nPCR) and in 
situ PCR. Because application of PCR technology 
for the detection of viral nucleic acid allows one to 
detect both latent and replicating viral sequences, 
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this approach should be expanded for the detection 
of  HCMV late transcript, which may better reflect 
productive viral replication (Taylor-Wiedeman et al., 
1991; Gozlan et al., 1992). 
MATERIALS AND METHODS
Clinical specimens. Forty samples of leuko-
cytes obtained from 32 patients after bone marrow 
transplantation (BMT) in different stages of treat-
ment (1–24 months after transplantation, average 7.0 
± 6.0) were investigated. Leukocytes were isolated 
by sedimentation of 3–5 ml EDTA-treated blood 
samples with 6% dextran solution (The et al., 1995). 
The upper part was collected after 30 min incuba-
tion at 37oC and centrifuged at 600 × g for 15 min. 
The contaminating erythrocytes were lysed with 
0.75% NH4Cl solution at 4oC for 10 min. Aliquots of 2 
× 105 leukocytes per slide were used to prepare cyt-
ospins. The slides were fixed in 10% buffered forma-
lin for 4 h (in situ PCR and in situ RT-PCR) or in 
5% buffered formalin for 15 min (antigenemia pp65). 
The remaining leukocytes (1 × 106 cells) were used 
to obtain DNA, which was isolated using Genomic 
DNA Prep Plus (A & A Biotechnology).
pp65 antigenemia. Monoclonal antibodies 
NCL–HCMV pp65 (Novocastra) were used. The 
HCMV pp65 antigen was detected according to Ger-
na et al. (1992).
Nested PCR. Two pairs of primers to amplify 
the gene encoding viral glycoprotein B (gB) accord-
ing to Mitchel et al. (1994) were used. The “outer” 
set was 5’-GTCGACGGTGGAGATACTGCTGAGG-
3’ and 5’-GAGGACAACGAAATCCTGTTGGGCA-
3’, which amplifies a 150 bp sequence. The “inner” 
primer pair was 5’-ACCACCGCACTGAGGAATGT-
CAG-3’ and 5’-TCAATCATGCGTTTGAGGAGGTA-
3’, which amplifies a 100 bp sequence.
The material for amplification was 20 ng of 
DNA isolated from leukocytes. The reaction took place 
in a thermocycler (Biometra) in buffer containing 10 
mM Tris/HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 
1 U of Taq polymerase DyNAzymeTM (Finnezymes), 
200 μM dNTP and 100 ng of each primer. Samples 
were amplified for 35 cycles under the following con-
ditions: 94oC for 5 min (first denaturation), 95oC for 2 
min, 58oC for external primers and 50oC for internal 
primers for 2 min, 72oC for 1 min, followed by a final 
elongation step of 72oC for 7 min. All amplifications 
were carried out with negative and positive controls. 
A check for the presence of Taq DNA polymerase in-
hibitors was performed by adding 2 ng of DNA (ob-
tained from a cell culture infected with the AD-169 
strain of HCMV) to the negative samples and retest-
ing. The PCR products were visualized by electro-
phoresis in 2% agarose gel with ethidium bromide.
In situ PCR. In situ PCR was done according to 
the protocol based on Lewis (1996) and Nuovo (1996). 
The appropriate sample was digested with pepsin (2 
mg/ml) for 30 min and afterwards inactivated in 100% 
ethanol. The reaction was carried out in a thermocy-
cler (Perkin Elmer). A volume of 25 μl of reaction 
mixture was applied onto the slide. The mixture con-
tained 1 μM primers; 200 μM nucleotides; 20 μM di-
goxigenin-labeled dUTP (DIG-dUTP, Applied Biosys-
tems); 4.5 or 5 mM MgCl2, 0.2 U/ μl polymerase Taq 
IS or Stoffel Fragment and 1 × buffer (pH 8.3, 100 mM 
Tris/HCl, 500 mM KCl/10×) for IS polymerase or 1 × 
buffer (pH 8.3, 100 mM Tris/HCl, 100 mM KCl/10×) 
for Stoffel Fragment. A suitable concentration of mag-
nesium chloride was established, 4.5 mM and 5 mM 
for IS polymerase and Stoffel Fragment, respectively. 
In addition to the primers for the gene coding for 
gB, primers for the gene encoding phosphoprotein 
pp65 (fluorescently labeled) were also used (Zaia et 
al., 2001). The “outer” primers were MP1 (5’-CTCG-
TAACCACCGAGCGCAAG-3’) and AP4 (5’-TCAAC-
CTCGGTGCTTTTTGGGCG-3’), the “inner” primers 
RAP1 (5’-GGATTCCGACAACGAAATCCAC-3’) and 
AP5 (5’-ATACGCTTCCAATTCGGCGAA-3’) yielding 
PCR products of 458 bp in the first run and 171 bp in 
the second.
For amplification of the target sequences, a 
modified program of two cycles was used: 94oC for 
3 min in the first cycle, and 20 repetitions of 94oC 
for 45 s and 60oC for 1.5 min in the second cycle 
(Nuovo, 1996). The hapten, incorporated into the 
amplified product, was detected using anti-digoxi-
genin antibodies conjugated to alkaline phosphate. 
The signal, resulting from the activity of the alkaline 
phosphate in the presence of nitroblue tetrazolium 
(NBT) and 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP), was obtained according to the manufactur-
er’s instructions (Boehringer Mannheim). The signal 
resulting from fluorescein was detected under a flu-
orescent microscope. 
In situ RT-PCR. Samples were prepared in 
the same way as for in situ PCR. After pepsin treat-
ment the samples were incubated in DNase solution 
(1 U/μl) at 37oC for 12 h. Reaction was carried out 
in the thermocycler (Perkin Elmer), 25 μl of reac-
tion mixture was applied onto the slide. The mix-
ture contained 1 × buffer EZ (Applied Biosystems), 
4 mM MnCl2, 300 μM dNTP, 15 μM DIG-dUTP, 
1 μM of each primer specific for gB, 0.2 U/ μl rTth 
DNA polymerase, which has both polymerase and 
reverse transcriptase activity (Applied Biosystems), 
0.5 U/ μl RNasin (Applied Biosystems). The RT-PCR 
assay was performed under the following condi-
tions: 65oC for 30 min, preliminary denaturation at 
94oC for 3 min, 20 cycles at 60oC for 1.5 min and 
94oC for 45 s. Detection was carried out in the same 
way as for in situ PCR.
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RESULTS
In 28 samples of peripheral leukocytes, pp65 
antigen was present in the cytoplasm (Fig. 1). Among 
the 12 samples without the pp65 antigen, two were 
obtained from seronegative recipients without history 
of HCMV infection. They were used as a negative 
control. All 40 samples were retested using nPCR, in 
situ PCR and in situ RT-PCR. Additionally, we used 
controls without polymerase or primers, which were 
helpful in correct interpretation of the results in the “in 
situ” methods. In some cases this evaluation was es-
sential because of the repair ability of DNA polymer-
ase. The results obtained by pp65 antigenemia, nPCR, 
in situ PCR and in situ RT-PCR are presented in Table 
1. Using nPCR, viral DNA was detected in 27 clini-
cal specimens, seven samples were negative. In the 
remaining six samples the results were unreadable 
due to the presence of polymerase inhibitors. The 
amplification results of these specimens in the pres-
ence of 2 ng of DNA positive for HCMV were also 
negative. In 20 blood samples we detected the viral 
DNA in the nucleus and/or cytoplasm of investigated 
cells by in situ PCR. In the same samples we found 
late viral transcripts using in situ RT-PCR, which con-
firmed productive infection. Figures 2 and 3 show 
examples of the results obtained with in situ PCR us-
ing different techniques of visualizing positive signal. 
Figure 2 shows results of  in situ PCR with primers 
for the gene coding for the protein gB detected with 
anti-digoxigenin antibodies conjugated to alkaline 
phosphatase. Figure 3 shows results of  in situ PCR 
with fluorescently labeled primers for the UL83 gene, 
coding for late pp65 protein. Figure 4 shows result of 
in situ RT-PCR reaction with primers for the gene en-
coding gB.
In eight pp65-positive samples in which the 
in situ RT-PCR results were negative the presence 
of CMV antigen in the cytoplasm could probably be 
due to phagocytosis (the presence of DNA in the cy-
toplasm was also detected by in situ PCR – Fig. 3). 
Among antigenemia-negative specimens, the latent 
form of HCMV was recognized in five samples on 
the basis of  HCMV DNA presence in the nucleus 
(Fig. 2) and absence of transcripts for late viral genes 
(gB) using the in situ methods. 
Figure 1. Example of HCMV pp65-antigen presence in 
the cytoplasm of peripheral blood leukocytes in cytospin 
preparation-immunofluorescein staining (magnification 
250×).
Table 1. Results of HCMV DNA or mRNA detection in 40 blood samples obtained by three methods, as related to the 
presence or absence of pp65 antigen in cytoplasm of leukocytes.
Conclusion of investigation No. of samples Ag pp65 nPCR PCR in situ RT–PCR in situ
Productive infection
15 + + + (N/C*) +
5 + inh** + (N/C) +
Phagocytosis
7 + + + (C) –
1 + inh + (C) –
Latent infection 5 – + + (N) –
Lack of infection 5 – – – –
Negative control 2 – – – –
+, positive result; –, negative result; *signal localization: N, nucleus; C, cytoplasm; **inhibitors of PCR reaction
Figure 2. The presence of HCMV DNA in the nucleus 
of peripheral blood leukocytes obtained by in situ PCR 
with primers specific for gene coding for gB HCMV 
(magnification 400×).
460	 	 	 	 	 	 	 	 	 	 	 	 2006B. Zawilinska and others
DISCUSSION
In immunocompromised patients, especially 
after organ transplantation, rapid, sensitive and re-
liable detection of HCMV infection is necessary 
(Amorim et al., 2001). 
Quantitative pp65 — antigenemia assay is re-
garded as a valuable and sensitive tool for predicting 
HCMV disease although interpretation of its results 
is not straightforward. Most instructions recommend 
recording cells with only nuclear fluorescence. In 
our prior study such cells were found rarely, mainly 
in patients with symptoms of HCMV disease, while 
leukocytes with a positive signal in the cytoplasm 
occurred quite frequently (Piatkowska-Jakubas et 
al., 2003). In such cases we used additional tests, in 
situ PCR and in situ RT-PCR, which confirmed the 
results of our antigenemia test and explained the 
source of the pp65 antigen in the cytoplasm of leu-
kocytes. On the basis of the in situ methods, in eight 
samples we detected the antigen that could be de-
rived by phagocytosis.
Nested PCR with its high sensitivity is useful 
as a screening test but this approach cannot discrim-
inate between latent and productive infection. In this 
situation it should be supplemented with quantita-
tive methods or detection of specific viral transcripts 
as well as in situ methods (Gerna et al., 2000; Kosz-
Vnenchak et al., 2001; Yakushiji et al., 2002; Nitsche 
et al., 2003; Ikewaki et al., 2005).
In situ PCR is the coupling of a PCR assay 
and nucleic acid hybridization. It allows for detec-
tion and visualization of the nucleic acid in ques-
tion within leukocytes, in the nucleus or cytoplasm 
(Komminoth & Long, 1995; Kosz-Vnenchak et al., 
2001). This is important for confirmation of latent 
infection, especially when other results are ambigu-
ous. We confirmed five such cases with latent in-
fection, which we used as negative controls. In situ 
PCR makes it possible to achieve high sensitivity, 
but it may cause non-specific signals as a result of 
mispriming, DNA repair or diffusion of the prod-
uct (Komminoth & Long, 1995). Because of this, one 
should carry out control experiments in order to 
evaluate the results in a proper way. In using in situ 
methods the main problem was high background.
The presence of viral mRNA is considered 
the most important indicator of active viral replica-
tion (Gozlan et al., 1992; Deiman et al., 2002). In our 
study, in situ RT-PCR detecting late HCMV tran-
scripts, such as mRNA for glycoprotein gB, was 
used to confirm productive viral infection. In 20 
samples we detected active HCMV replication and 
in 13 specimens phagocytosis or latency was prob-
able. In all these cases in situ methods were very 
helpful. In samples in which it was impossible to 
carry out nPCR because of the presence of polymer-
ase inhibitors, the in situ methods played a crucial 
role in proper diagnosis.
Acknowledgement
This research was supported by grant 3 P04C 
023 25 from the Ministry of Scientific Research and 
Information Technology.
REFERENCES
Alford CA, Britt WJ (1996) Cytomegalovirus. In Virology 
(Fields BN, Knipe DM, eds) pp 2494–2512, Lippincott-
Raven Publishers, Philadelphia. 
Amorim ML, Cabeda JM, Seca R, Mendes AC, Castro AP, 
Amorim JM (2001) Cytomegalovirus infection of liver 
transplant recipients; comparison of antigenemia and 
molecular biology assays. Liver Transplant 11: 1004–
1007.
Figure 3. The presence of HCMV DNA in the cytoplasm 
of peripheral blood leukocytes obtained by in situ PCR 
with fluorescently labeled primers specific for UL83 gene 
encoding pp65 protein (magnification 400×).
Figure 4. The presence of HCMV transcripts in the cy-
toplasm of blood leukocytes obtained by in situ RT-
PCR with primers for gene coding for gB (magnification 
400×).
Vol.	 53	 	 	 	 	 	 	 461In situ methods for HCMV detection
Boeckh M, Boivin G (1998) Quantitation of CMV; method-
ological aspects and clinical applications. Clin Microbiol 
Rev 3: 533–554. 
Deiman B, van Aarle P, Sillekens P (2002) Characteristics 
and applications of nucleic acid sequence-based ampli-
fication (NASBA). Mol Biotech 20: 163–179. 
Gerna GM, Revello G, Percivalle E, Morini F  (1992) Com-
parison of different immunostaining techniques and 
monoclonal antibodies to the lower matrix phospho-
protein (pp65) for optimal quantification of human 
cytomegalovirus antigenemia. J Clin Microbiol 30: 1232–
1237.
Gerna G, Baldanti F, Pesea M, Alessandrino E, Pagani A, 
Locatelli F, Middeldorp J, Revello MG (2000) Human 
cytomegalovirus immediate early mRNA detection by 
nucleic acid sequence-based amplification as a new pa-
rameter for preemptive therapy in bone marrow trans-
plant recipients. J Clin Microbiol 38: 1845–1853. 
Gozlan J, Caburet F, Trancrede C, Petit JC (1992) A reverse 
polymerase chain reaction method for detection of hu-
man cytomegalovirus late transcripts in cells infected 
in vitro. J Virol Methods 40: 1–10.
Hengel H, Brune B, Koszinowski UH (1998) Immune eva-
sion by cytomegalovirus-survival strategies of a highly 
adapted opportunist. Trends Microbiol 6: 190–197.
Ikewaki J, Ohtsuka E, Kawano R, Ogata M, Kikuchi H, 
Nasu M (2005) Real-time PCR assays based on distinct 
genomic regions for cytomegalovirus reactivation fol-
lowing hematopoietic stem cell transplantation. Bone 
Marrow Transplant 35: 403–410.
Kas-Deelen AM, The TH, Bloom N, van der Strate BW, De 
Maar EF, Smit J, van Son WJ, Harmsen MC (2001) Up-
take of pp65-positive polymorphonuclear cells medi-
ated by phagocytosis and cell fusion? Intervirology 44: 
8–13.
Komminoth P, Long AA (1995) In situ polymerase chain 
reaction–methodology, application and non-specific 
pathways. In PCR Applications Manual, pp 99–106, 
Boehringer Mannheim GmbH.
Kosz-Vnenchak M, Grabiec A, Zawilinska B (2001) Appli-
cation of PCR in situ method for detection of HCMV 
DNA. Acta Microbiol Pol 2: 169–173.
Lewis F (1996) An Approach to in situ PCR. PE Applied Bio-
systems, A Division of The Perkin-Elmer Corporation.
Mitchell SM, Fox JD, Tedder RS, Gazzard BG, Lightman S 
(1994) Vitrous fluid sampling and viral genome detec-
tion for the diagnosis of viral retinitis in patients with 
AIDS. J Med Virol 43: 336–340.
Nitsche A, Oswald O, Schetelig J, Radonic A, Thulke S, 
Siegert W (2003) Quantitative real-time PCR com-
pared with pp65 antigen detection for cytomegalovi-
rus (CMV) in 1122 blood specimens from 77 patients 
after allogenic stem cell transplantation: which test bet-
ter predicts CMV disease development? Clin Chem 49: 
1683–1685.
Nuovo GJ (1996) PCR in situ Hybridization. Protocolos and 
Applications, 3th edn, Lippincott, Raven Press New 
York.
Perez JL, Mariscal D, Tubau F, Niubo J, Martin R (1994) 
Evaluation of the CMV-vue antigenemia assay for 
rapid detection of cytomegalovirus in peripheral blood 
leukocytes. Diagn Microbiol Infect Dis 19: 15–18. 
Piatkowska-Jakubas B, Zawilinska B, Kopec J, Rojek-Za-
krzewska D, Koprynia M, Polus A, Skotnicki A (2003) 
Antigenemia pp65 assay and qualitative CMV DNA 
PCR assay for monitoring cytomegalovirus infection in 
allogeneic stem cell transplant recipients-own experi-
ence. Acta Haematol Polon 34: 339–346.
Preiser W, Bräuninger S, Schwerdtfeger R, Ayliffe U, Gar-
son JA, Brink NS, Franck S, Doerr HW, Rabenau HF 
(2001) Evaluation of diagnostic methods for the detec-
tion of cytomegalovirus in recipients after allogenic 
stem cell transplants. J Clin Virol 20: 59–70.
Razonable RR, Paya CV, Smith TF (2002) Role of the labo-
ratory in diagnosis and management of cytomegalo-
virus infection in hematopoietic stem cell and solid-
organ transplant recipients. J Antimicrob Chemoter 49: 
243–253.
Schafer P, Tenschert W, Gutensohn K, Laufs R (1997) Min-
imal effect of delayed sample processing on results of 
quantitative PCR for cytomegalovirus DNA in leuko-
cytes compared to results of an antigenemia assay. J 
Clin Microbiol 35: 741–744.
Streblow DN, Nelson JA (2003) Models of HCMV latency 
and reactivation. Trends Microbiol 7: 293–295.
Taylor-Wiedeman JA, Sissons JPG, Borysiewicz IK, Sinclair 
JH (1991) Monocytes are a major site of persistence of 
human cytomegalovirus in peripheral blood mononu-
clear cells. J Gen Virol 72: 2059–2064.
The TH, van der Berg AP, Harmsen MC, van der Bij W, 
van Son WJ (1995) The cytomegalovirus antigenemia 
assay: a plea for standarization. Scan J Infect Dis 99: 
25–29.
Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hay-
ashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, 
Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, 
Okamura T, Kinukawa N, Kasuga N, Sata M, Harada 
M (2002) Monitoring of cytomegalovirus after allogenic 
stem cell transplantation: comparison of an antigene-
mia assay and quantitative real-time polymerase chain 
reaction. Bone Marrow Transplant 29: 599–606.
Zaia JA, Gallez–Hawkins G, Li X, Yao ZQ, Lomeli N, Mo-
linder K, La Rosa C, Diamond DJ (2001) Infrequent oc-
currence of natural mutations in the pp65495-503 epitope 
sequence presented by HLA A*0201 allele among hu-
man cytomegalovirus isolates. J Virol 5: 2472–2474.
